-
Notifications
You must be signed in to change notification settings - Fork 1
/
acr-appropriateness-criteria--colorectal-cancer-screening
1277 lines (1164 loc) · 120 KB
/
acr-appropriateness-criteria--colorectal-cancer-screening
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
<!DOCTYPE html>
<html lang="en">
<head><script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app43.us.archive.org';v.server_ms=1386;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />
<!-- End Wayback Rewrite JS Include -->
<title>ACR Appropriateness Criteria&reg; colorectal cancer screening. | National Guideline Clearinghouse</title>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width">
<link rel="icon" href="/web/20180713052618im_/https://www.guideline.gov/UI/images/favicon-NGC.ico">
<link rel="apple-touch-icon" sizes="180x180" href="/web/20180713052618im_/https://www.guideline.gov/UI/images/apple-touch-icon-NGC.png">
<link rel="icon" type="image/png" href="/web/20180713052618im_/https://www.guideline.gov/UI/images/favicon-NGC-32x32.png" sizes="32x32">
<link rel="icon" type="image/png" href="/web/20180713052618im_/https://www.guideline.gov/UI/images/favicon-NGC-16x16.png" sizes="16x16">
<link rel="manifest" href="/web/20180713052618/https://www.guideline.gov/UI/images/manifest-NGC.json">
<link rel="mask-icon" href="/web/20180713052618im_/https://www.guideline.gov/UI/images/safari-pinned-tab-NGC.svg" color="#1d4345">
<meta name="theme-color" content="#ffffff">
<link href="/web/20180713052618cs_/https://www.guideline.gov/cassette.axd/stylesheet/8382974d7bae1577062376dcd37102348398fe04/NGCSiteCSS" type="text/css" rel="stylesheet"/>
<!--[if lt IE 9]>
<link href="/cassette.axd/stylesheet/2188ac5b8507764bb4079068f7a3c8d7ccfba0e7/ieCSS" type="text/css" rel="stylesheet"/>
<![endif]-->
<script async type="text/javascript" id="_fed_an_ua_tag" src="https://web.archive.org/web/20180713052618js_/https://dap.digitalgov.gov/Universal-Federated-Analytics-Min.js?agency=HHS&subagency=AHRQ"></script>
</head>
<body class="no-js content-page">
<a href="#main-content" id="skip-nav">Skip to main content</a>
<!--https://developers.google.com/tag-manager/devguide#multidomain ECH-1199-->
<!-- Google Tag Manager -->
<noscript>
<iframe src="//web.archive.org/web/20180713052618if_/https://www.googletagmanager.com/ns.html?id=GTM-W4NX5V" height="0" width="0" style="display:none;visibility:hidden"></iframe>
</noscript>
<script>
(function (w, d, s, l, i) {
w[l] = w[l] || []; w[l].push({
'gtm.start':
new Date().getTime(), event: 'gtm.js'
}); var f = d.getElementsByTagName(s)[0],
j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
'//web.archive.org/web/20180713052618/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
})(window, document, 'script', 'dataLayer', 'GTM-W4NX5V');</script>
<noscript>
<iframe src="//web.archive.org/web/20180713052618if_/https://www.googletagmanager.com/ns.html?id=GTM-KHDP6Z" height="0" width="0" style="display:none;visibility:hidden"></iframe>
</noscript>
<script>
(function (w, d, s, l, i) {
w[l] = w[l] || []; w[l].push({
'gtm.start':
new Date().getTime(), event: 'gtm.js'
}); var f = d.getElementsByTagName(s)[0],
j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
'//web.archive.org/web/20180713052618/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
})(window, document, 'script', 'dataLayer', 'GTM-KHDP6Z');</script>
<!-- End Google Tag Manager -->
<!-- AHRQ HEADER -->
<div id="ahrq-header">
<p class="hhs-links">
<a href="https://web.archive.org/web/20180713052618/http://www.hhs.gov/" target="_blank" class="logo-hhs"><span class="logomark"></span>U.S. Department of Health and Human Services</a>
<a href="https://web.archive.org/web/20180713052618/http://www.hhs.gov/" target="_blank" class="external-link"><strong>HHS.gov</strong></a>
</p><!-- /.hhs-links -->
<p class="ahrq-links">
<a href="https://web.archive.org/web/20180713052618/http://www.ahrq.gov/" target="_blank" class="logo-ahrq">Agency for Healthcare Research and Quality: Advancing Excellence in Health Care</a>
<a href="https://web.archive.org/web/20180713052618/http://www.ahrq.gov/" target="_blank" class="external-link"><strong>AHRQ.gov</strong></a>
</p><!-- /.ahrq-links -->
</div><!-- /#ahrq-header -->
<!-- HEADER -->
<div class="header" id="header">
<div class="masthead">
<ul class="header-actions">
<li><a href="#header-search" class="search-action"><span class="label">Search</span></a></li>
<li><a href="#header-account" class="account-action"><span class="label">Account</span></a></li>
<li><a href="#main-nav" class="menu-action"><span class="label">Menu</span></a></li>
</ul><!-- /.header-actions -->
<a href="/web/20180713052618/https://www.guideline.gov/" class="header-logo NGC">
<picture>
<source media="(min-width: 960px)" srcset="/web/20180713052618im_/https://www.guideline.gov/UI/images/logo_NGC_header.png">
<source srcset="/web/20180713052618im_/https://www.guideline.gov/UI/images/logo_NGC_header_m.png">
<img src="/web/20180713052618im_/https://www.guideline.gov/UI/images/logo_NGC_header.png" alt="National Guideline Clearinghouse">
</picture>
</a>
<form action="/web/20180713052618/https://www.guideline.gov/search" class="header-search header-action" enctype="multipart/form-data" id="header-search" method="get"> <p class="search-bar">
<label for="q"><span class="screen-reader-text">Search</span>
<input id="q" type="text" title="Search Input" name="q" class="search-input" placeholder="Search">
</label>
<input id="masthead-search-button" type="submit" title="Search Submit" class="search-submit" value="Search">
</p>
<p class="search-tips">
<a href="/web/20180713052618/https://www.guideline.gov/help-and-about/search-browse/search-tips">Search Tips</a>
</p>
</form> <div class="header-account header-action" id="header-account">
<a id="login-button" class="signin" href="/web/20180713052618/https://www.guideline.gov/accounts/signinlanding" aria-role="tab" aria-controls="login-panel" aria-selected="false">Log into My NGC</a>
<div id="login-panel" class="login dropdown" aria-role="tab-panel" aria-labeledby="login-button" aria-hidden="true">
<div class="sign-in">
<form id="sign-in-form" action="/web/20180713052618/https://www.guideline.gov/Accounts/LoginSubmit" method="post">
<h3>Sign In</h3>
<div class="errormessages"></div>
<p class="invalid-user-cred message-block" style="display: none;"></p>
<p>
<label for="sign-in-username">Username or Email <span class="required">*</span></label>
<input type="text" id="sign-in-username" class="input-text" name="email" required>
</p>
<p>
<label for="sign-in-userpwd">Password <span class="required">*</span></label>
<input type="password" id="sign-in-userpwd" class="input-text" name="password" required>
</p>
<p class="form-link"><a href="/web/20180713052618/https://www.guideline.gov/accounts/forgotpassword">Forgot Password?</a></p>
<p><label for="remember-me"><input type="checkbox" name="remember-me" id="remember-me">Remember Me</label></p>
<input id="account-sign-in" type="submit" value="Sign In"/>
</form>
<p>
<label for="sign-up-btn">Don't have an account?</label>
<a href="/web/20180713052618/https://www.guideline.gov/accounts/login" class="sign-up-btn" id="sign-up-btn">Create New Account</a>
</p>
</div><!--/.sign-in-->
</div><!-- /.login -->
</div><!-- /.header-account -->
</div><!-- /.masthead -->
<div class="main-nav header-action" id="main-nav">
<ul class="level-1">
<li class=""><a href="/web/20180713052618/https://www.guideline.gov/">Home</a></li>
<li class=""><a href="/web/20180713052618/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
<li>
<a href="/web/20180713052618/https://www.guideline.gov/summaries/browse" class="parent-link">Guideline Summaries</a> <ul class="level-2 dropdown">
<li class=""><a href="/web/20180713052618/https://www.guideline.gov/browse/clinical-specialty">By Clinical Specialty</a></li>
<li class=""><a href="/web/20180713052618/https://www.guideline.gov/browse/organization">By Organization</a></li>
<li class=""><a href="/web/20180713052618/https://www.guideline.gov/browse/mesh-tag">By MeSH Tag</a></li>
<li class=""><a href="/web/20180713052618/https://www.guideline.gov/summaries/in-progress">In Progress</a></li>
<li class=""><a href="/web/20180713052618/https://www.guideline.gov/summaries/archive">Archive</a></li>
<li class=""><a href="/web/20180713052618/https://www.guideline.gov/search?f_DocType=0&fLockTerm=Guideline Summaries">All Summaries</a></li>
</ul>
</li>
<li class=""><a href="/web/20180713052618/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li> <li class=""><a href="/web/20180713052618/https://www.guideline.gov/expert">Expert Commentaries</a></li>
<li class=""><a href="/web/20180713052618/https://www.guideline.gov/matrix">Matrix Tool</a></li>
<li class="">
<a href="/web/20180713052618/https://www.guideline.gov/summaries/submit">Submit Guidelines</a> </li>
<li class=""><a href="/web/20180713052618/https://www.guideline.gov/help-and-about">Help & About</a></li>
</ul>
</div><!-- /.main-nav -->
</div><!-- /.header -->
<br/><div class="content"><div class="fundingNotice2"><b>The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018</b> because federal funding <br/>through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our <a href="/web/20180713052618/https://www.guideline.gov/home/announcements">full announcement</a>.</div></div>
<!-- CONTENT -->
<main id="main-content" tabindex="-1">
<div class="main">
<div class="aside-container">
<div class="content">
<!-- CONTENT HEADER -->
<div class="content-header">
<ul class="content-header-meta">
<li class="prefix-icon guideline">Guideline Summary</li>
<li>NGC:010144</li>
<li>1998 (revised 2013)
</li>
</ul>
<div>
<h1>ACR Appropriateness Criteria® colorectal cancer screening.</h1>
</div>
</div>
<!-- /.content-header-meta -->
<!-- CONTENT TABS -->
<ul class="content-tabs">
<li><a href="#developer-tab" class="developer is-active"><span class="label">Developer</span></a></li>
<li><a href="#source-tab" class="source"><span class="label">Source</span></a></li>
<li><a href="#status-tab" class="status"><span class="label">Status</span></a></li>
<li><a href="#classification-tab" class="classification"><span class="label">Classification</span></a></li>
</ul>
<div id="developer-tab" class="is-active content-tab-panel">
<ul class="developer-list">
<li><a href="/web/20180713052618/https://www.guideline.gov/search?f_Guideline_Developer_String=American%20College%20of%20Radiology&fLockTerm=American%2BCollege%2Bof%2BRadiology">American College of Radiology</a></li>
<li>
<a id="246" href="#" data-alert="SignInLanding" data-alert-type="organization" class="get-alerts get-org-alerts">Get Alerts</a>
</li>
</ul>
</div>
<!-- /.content-tab-panel -->
<div id="source-tab" class="content-tab-panel">
<table><tr><td>Yee J, Kim DH, Rosen MP, Lalani T, Carucci LR, Cash BD, Feig BW, Fowler KJ, Katz DS, Smith MP, Yaghmai V, Expert Panel on Gastrointestinal Imaging. ACR Appropriateness Criteria® colorectal cancer screening. [online publication]. Reston (VA): American College of Radiology (ACR); 2013. 12 p. [90 references]</td></tr></table> <p><a href="/web/20180713052618/https://www.guideline.gov/Home/Disclaimer?id=47650&contentType=fulltextlink&redirect=https%253a%252f%252facsearch.acr.org%252fdocs%252f69469%252fNarrative">View the original guideline documentation</a> <img alt="External Web Site Policy" src="/web/20180713052618im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></p>
</div>
<!-- /.content-tab-panel -->
<div id="status-tab" class="content-tab-panel">
<p><div class="content_para"><p>This is the current release of the guideline.</p>
<p>This guideline updates a previous version: Yee J, Rosen MP, Blake MA, Baker ME, Cash BD, Fidler JL, Grant TH, Greene FL, Jones B, Katz DS, Lalani T, Miller FH, Small WC, Sudakoff GS, Warshauer DM, Expert Panel on Gastrointestinal Imaging. ACR Appropriateness Criteria® colorectal cancer screening. [online publication]. Reston (VA): American College of Radiology (ACR); 2010. 9 p.</p></div></p>
</div>
<!-- /.content-tab-panel -->
<div id="classification-tab" class="content-tab-panel">
<h4>Age Group</h4>
<ul>
<li><a href="/web/20180713052618/https://www.guideline.gov/search?f_Age_of_Target_Population=Adult%20%2819%20to%2044%20years%29&fLockTerm=Adult%2B%2819%2Bto%2B44%2Byears%29">Adult (19 to 44 years)</a></li>
<li><a href="/web/20180713052618/https://www.guideline.gov/search?f_Age_of_Target_Population=Middle%20Age%20%2845%20to%2064%20years%29&fLockTerm=Middle%2BAge%2B%2845%2Bto%2B64%2Byears%29">Middle Age (45 to 64 years)</a></li>
<li><a href="/web/20180713052618/https://www.guideline.gov/search?f_Age_of_Target_Population=Aged%20%2865%20to%2079%20years%29&fLockTerm=Aged%2B%2865%2Bto%2B79%2Byears%29">Aged (65 to 79 years)</a></li>
<li><a href="/web/20180713052618/https://www.guideline.gov/search?f_Age_of_Target_Population=Aged%2C%2080%20and%20over&fLockTerm=Aged%252c%2B80%2Band%2Bover">Aged, 80 and over</a></li>
</ul>
<h4>UMLS Concepts <a href="/web/20180713052618/https://www.guideline.gov/help-and-about/search-browse/umls-concepts" class="what-is">(what is this?)</a></h4>
<div class="field">
<h5 class="field-label">ICD9CM</h5>
<div class="field-content">
<a href="/web/20180713052618/https://www.guideline.gov/search?f_ICD9CM_CUI=C0203075&fLockTerm=Lower+GI+series">Lower GI series</a>
(87.64), <a href="/web/20180713052618/https://www.guideline.gov/search?f_ICD9CM_CUI=C0007102&fLockTerm=Malignant+neoplasm+of+colon%2c+unspecified+site">Malignant neoplasm of colon, unspecified site</a>
(153.9), <a href="/web/20180713052618/https://www.guideline.gov/search?f_ICD9CM_CUI=C0949022&fLockTerm=Malignant+neoplasm+of+rectum">Malignant neoplasm of rectum</a>
(154.1) </div>
<!-- /.field-content -->
</div>
<!-- /.field -->
<div class="field">
<h5 class="field-label">MSH</h5>
<div class="field-content">
<a href="/web/20180713052618/https://www.guideline.gov/search?f_MSH_CUI=C0203075&fLockTerm=Barium+Enema">Barium Enema</a>
, <a href="/web/20180713052618/https://www.guideline.gov/search?f_MSH_CUI=C0935912&fLockTerm=Colonography%2c+Computed+Tomographic">Colonography, Computed Tomographic</a>
, <a href="/web/20180713052618/https://www.guideline.gov/search?f_MSH_CUI=C0009404&fLockTerm=Colorectal+Neoplasms">Colorectal Neoplasms</a>
, <a href="/web/20180713052618/https://www.guideline.gov/search?f_MSH_CUI=C0009924&fLockTerm=Contrast+Media">Contrast Media</a>
, <a href="/web/20180713052618/https://www.guideline.gov/search?f_MSH_CUI=C0011906&fLockTerm=Diagnosis%2c+Differential">Diagnosis, Differential</a>
, <a href="/web/20180713052618/https://www.guideline.gov/search?f_MSH_CUI=C2607925&fLockTerm=Early+Detection+of+Cancer">Early Detection of Cancer</a>
, <a href="/web/20180713052618/https://www.guideline.gov/search?f_MSH_CUI=C0024485&fLockTerm=Magnetic+Resonance+Imaging">Magnetic Resonance Imaging</a>
, <a href="/web/20180713052618/https://www.guideline.gov/search?f_MSH_CUI=C0936234&fLockTerm=Tomography+Scanners%2c+X-Ray+Computed">Tomography Scanners, X-Ray Computed</a>
</div>
<!-- /.field-content -->
</div>
<!-- /.field -->
<div class="field">
<h5 class="field-label">MTH</h5>
<div class="field-content">
<a href="/web/20180713052618/https://www.guideline.gov/search?f_MTH_CUI=C0009402&fLockTerm=Colorectal+Carcinoma">Colorectal Carcinoma</a>
, <a href="/web/20180713052618/https://www.guideline.gov/search?f_MTH_CUI=C0935912&fLockTerm=Computed+Tomographic+Colonography">Computed Tomographic Colonography</a>
, <a href="/web/20180713052618/https://www.guideline.gov/search?f_MTH_CUI=C0936234&fLockTerm=Computed+Tomography+Scanning+Systems">Computed Tomography Scanning Systems</a>
, <a href="/web/20180713052618/https://www.guideline.gov/search?f_MTH_CUI=C0009924&fLockTerm=Contrast+Media">Contrast Media</a>
, <a href="/web/20180713052618/https://www.guideline.gov/search?f_MTH_CUI=C0011906&fLockTerm=Differential+Diagnosis">Differential Diagnosis</a>
, <a href="/web/20180713052618/https://www.guideline.gov/search?f_MTH_CUI=C2607925&fLockTerm=Early+Detection+of+Cancer">Early Detection of Cancer</a>
, <a href="/web/20180713052618/https://www.guideline.gov/search?f_MTH_CUI=C0024485&fLockTerm=Magnetic+Resonance+Imaging">Magnetic Resonance Imaging</a>
, <a href="/web/20180713052618/https://www.guideline.gov/search?f_MTH_CUI=C0949022&fLockTerm=Malignant+Rectal+Neoplasm">Malignant Rectal Neoplasm</a>
, <a href="/web/20180713052618/https://www.guideline.gov/search?f_MTH_CUI=C0007102&fLockTerm=Malignant+tumor+of+colon">Malignant tumor of colon</a>
, <a href="/web/20180713052618/https://www.guideline.gov/search?f_MTH_CUI=C0199230&fLockTerm=Screening+for+cancer">Screening for cancer</a>
</div>
<!-- /.field-content -->
</div>
<!-- /.field -->
<div class="field">
<h5 class="field-label">PDQ</h5>
<div class="field-content">
<a href="/web/20180713052618/https://www.guideline.gov/search?f_PDQ_CUI=C0203075&fLockTerm=barium+enema">barium enema</a>
, <a href="/web/20180713052618/https://www.guideline.gov/search?f_PDQ_CUI=C0024485&fLockTerm=magnetic+resonance+imaging">magnetic resonance imaging</a>
, <a href="/web/20180713052618/https://www.guideline.gov/search?f_PDQ_CUI=C0935912&fLockTerm=virtual+colonoscopy">virtual colonoscopy</a>
</div>
<!-- /.field-content -->
</div>
<!-- /.field -->
<div class="field">
<h5 class="field-label">SNOMEDCT_US</h5>
<div class="field-content">
<a href="/web/20180713052618/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0203075&fLockTerm=Barium+enema">Barium enema</a>
(168836005), <a href="/web/20180713052618/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0203075&fLockTerm=Barium+enema">Barium enema</a>
(265068003), <a href="/web/20180713052618/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0203075&fLockTerm=Barium+enema">Barium enema</a>
(303758005), <a href="/web/20180713052618/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0009924&fLockTerm=Contrast+media">Contrast media</a>
(385420005), <a href="/web/20180713052618/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0009924&fLockTerm=Contrast+media">Contrast media</a>
(407935004), <a href="/web/20180713052618/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0011906&fLockTerm=Differential+diagnosis">Differential diagnosis</a>
(47965005), <a href="/web/20180713052618/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0024485&fLockTerm=Magnetic+resonance+imaging">Magnetic resonance imaging</a>
(113091000), <a href="/web/20180713052618/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0024485&fLockTerm=Magnetic+resonance+imaging">Magnetic resonance imaging</a>
(312250003), <a href="/web/20180713052618/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0336660&fLockTerm=Magnetic+resonance+imaging+unit">Magnetic resonance imaging unit</a>
(90003000), <a href="/web/20180713052618/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0007102&fLockTerm=Malignant+tumor+of+colon">Malignant tumor of colon</a>
(363406005), <a href="/web/20180713052618/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0949022&fLockTerm=Malignant+tumor+of+rectum">Malignant tumor of rectum</a>
(363351006), <a href="/web/20180713052618/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0009404&fLockTerm=Neoplasm+of+large+intestine">Neoplasm of large intestine</a>
(126837005), <a href="/web/20180713052618/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0199230&fLockTerm=Screening+for+cancer">Screening for cancer</a>
(15886004) </div>
<!-- /.field-content -->
</div>
<!-- /.field -->
<div class="field">
<h5 class="field-label">SPN</h5>
<div class="field-content">
<a href="/web/20180713052618/https://www.guideline.gov/search?f_SPN_CUI=C0336660&fLockTerm=SYSTEM%2c+NUCLEAR+MAGNETIC+RESONANCE+IMAGING">SYSTEM, NUCLEAR MAGNETIC RESONANCE IMAGING</a>
, <a href="/web/20180713052618/https://www.guideline.gov/search?f_SPN_CUI=C0936234&fLockTerm=SYSTEM%2c+X-RAY%2c+TOMOGRAPHY%2c+COMPUTED">SYSTEM, X-RAY, TOMOGRAPHY, COMPUTED</a>
</div>
<!-- /.field-content -->
</div>
<!-- /.field -->
<div class="field">
<h5 class="field-label">UMD</h5>
<div class="field-content">
<a href="/web/20180713052618/https://www.guideline.gov/search?f_UMD_CUI=C0009924&fLockTerm=Contrast+Media">Contrast Media</a>
(16-573), <a href="/web/20180713052618/https://www.guideline.gov/search?f_UMD_CUI=C0936234&fLockTerm=Scanning+Systems%2c+Computed+Tomography">Scanning Systems, Computed Tomography</a>
(13-469), <a href="/web/20180713052618/https://www.guideline.gov/search?f_UMD_CUI=C0336660&fLockTerm=Scanning+Systems%2c+Magnetic+Resonance+Imaging">Scanning Systems, Magnetic Resonance Imaging</a>
(16-260) </div>
<!-- /.field-content -->
</div>
<!-- /.field -->
</div>
<!-- /.content-tab-panel -->
<!-- /.content-tab-panel -->
<!-- TOOLBAR -->
<div class="content-toolbar">
<!-- Primary -->
<ul class="tools primary-tools">
<li class="dropdown tool sections">
<a href="#" class="tool-button">Sections</a>
<div class="dropdown-panel">
<ul class="section-links">
<li><a href="#420" class="section-mark">Recommendations</a></li>
<li><a href="#396" class="section-mark">Scope</a></li>
<li><a href="#405" class="section-mark">Methodology</a></li>
<li><a href="#424" class="section-mark">Evidence Supporting the Recommendations</a></li>
<li><a href="#427" class="section-mark">Benefits/Harms of Implementing the Guideline Recommendations</a></li>
<li><a href="#430" class="section-mark">Contraindications</a></li>
<li><a href="#432" class="section-mark">Qualifying Statements</a></li>
<li><a href="#434" class="section-mark">Implementation of the Guideline</a></li>
<li><a href="#439" class="section-mark">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></li>
<li><a href="#442" class="section-mark">Identifying Information and Availability</a></li>
<li><a href="#99999" class="section-mark">Disclaimer</a></li>
</ul>
</div>
<!-- /.dropdown-panel -->
</li>
</ul>
<!-- Other -->
<ul class="tools other-tools">
<li class="dropdown tool">
<a href="#" class="tool-button">Download</a>
<div class="dropdown-panel">
<ul>
<li><a href="/web/20180713052618/https://www.guideline.gov/summaries/downloadcontent/ngc-10144?contentType=pdf" class="pdf">.PDF 121.4 kb</a></li>
<li><a href="/web/20180713052618/https://www.guideline.gov/summaries/downloadcontent/ngc-10144?contentType=word" class="word">Word Document 339.7 kb</a></li>
<li><a href="/web/20180713052618/https://www.guideline.gov/summaries/downloadcontent/ngc-10144?contentType=xml" class="xml">.XML 84.5 kb</a></li>
</ul>
</div>
<!-- /.dropdown-panel -->
</li>
<li class="dropdown tool">
<a href="#" class="tool-button">Share</a>
<div class="dropdown-panel">
<ul class="toolbar-social">
<li><a target="_blank" href="https://web.archive.org/web/20180713052618/https://www.facebook.com/sharer/sharer.php?u=https://www.guideline.gov/summaries/summary/47650/acr-appropriateness-criteria--colorectal-cancer-screening" class="facebook">Facebook</a></li>
<li><a target="_blank" href="https://web.archive.org/web/20180713052618/https://twitter.com/share?text=&url=https://www.guideline.gov/summaries/summary/47650/acr-appropriateness-criteria--colorectal-cancer-screening" class="twitter">Twitter</a></li>
<li><a target="_blank" href="https://web.archive.org/web/20180713052618/https://www.linkedin.com/shareArticle?mini=true&url=https://www.guideline.gov/summaries/summary/47650/acr-appropriateness-criteria--colorectal-cancer-screening&title=&summary=&source=" class="linkedin">Linkedin</a></li>
<li><a href="https://web.archive.org/web/20180713052618/mailto:/?Subject=AHRQ: ACR Appropriateness Criteria&amp;reg; colorectal cancer screening.&body=https://www.guideline.gov/summaries/summary/47650/acr-appropriateness-criteria--colorectal-cancer-screening" class="email">Email</a></li>
</ul>
</div>
<!-- /.dropdown-panel -->
</li>
<li class="dropdown tool">
<a href="#" class="tool-button">Cite</a>
<div class="dropdown-panel citation">
<p class="text-label"><label for="citation">Citation: </label></p>
<textarea id="citation">National Guideline Clearinghouse (NGC). Guideline summary: ACR Appropriateness Criteria® colorectal cancer screening. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2013 Jan 01. [cited 2018 Jul 13]. Available: https://www.guideline.gov</textarea>
<p class="text-label">Download citation file: </p>
<ul>
<li><a href="/web/20180713052618/https://www.guideline.gov/summaries/citedownload/47650?format=ris">RIS (Zotero)</a></li>
<li><a href="/web/20180713052618/https://www.guideline.gov/summaries/citedownload/47650?format=enw">EndNote</a></li>
<li><a href="/web/20180713052618/https://www.guideline.gov/summaries/citedownload/47650?format=bibtex">BibTex</a></li>
<li><a href="/web/20180713052618/https://www.guideline.gov/summaries/citedownload/47650?format=txt">Medlars</a></li>
<li><a href="/web/20180713052618/https://www.guideline.gov/summaries/citedownload/47650?format=ris">ProCite</a></li>
<li><a href="/web/20180713052618/https://www.guideline.gov/summaries/citedownload/47650">RefWorks</a></li>
<li><a href="/web/20180713052618/https://www.guideline.gov/summaries/citedownload/47650?format=ris">Reference Manager</a></li>
</ul>
</div>
<!-- /.dropdown-panel -->
</li>
<li class="tool">
<a href="#" id="47650" data-alert="SignInLanding" class="tool-button save-link">Save</a>
</li>
</ul>
<!-- Accordion -->
<ul class="tools accordion-controls">
<li class="tool"><a href="#" class="expand-all is-disabled" aria-disabled="true"><span class="screen-reader-text">Expand All</span></a></li>
<li class="tool"><a href="#" class="collapse-all" aria-disabled="false"><span class="screen-reader-text">Collapse All</span></a></li>
</ul>
</div>
<!-- /.toolbar -->
<!-- ARTICLE -->
<div class="article" id="article">
<!-- ACCORDION -->
<div class="accordion-container" role="tablist" multiselectable="true">
<h2 id="420" class="accordion-title section-420 is-active" role="tab" aria-expanded="true"><a href="#">Recommendations</a></h2>
<div class="accordion-panel is-active" role="tabpanel">
<h3><a href="#">Major Recommendations</a></h3>
<p><div class="content_para"><p><strong>ACR Appropriateness Criteria®</strong></p>
<p><strong><span style="text-decoration: underline;">Clinical Condition:</span> Colorectal Cancer Screening</strong></p>
<p><strong><span style="text-decoration: underline;">Variant 1:</span> Average-risk individual: age ≥50 years.</strong></p>
<table border="1" cellspacing="1" cellpadding="5" summary="Table: Variant 1: Average-risk individual: age greater than or equal to 50 years">
<thead>
<tr>
<th width="30%" class="Center" valign="bottom" scope="col">Radiologic Procedure</th>
<th width="20%" class="Center" valign="bottom" scope="col">Rating</th>
<th width="40%" class="Center" valign="bottom" scope="col">Comments</th>
<th width="25%" class="Center" valign="bottom" scope="col">RRL*</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top">CT colonography every 5 years after negative screen</td>
<td class="Center" valign="top">9</td>
<td valign="top"> </td>
<td class="Center" valign="top"><img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/></td>
</tr>
<tr>
<td valign="top">X-ray barium enema double-contrast every 5 years after negative screen</td>
<td class="Center" valign="top">6</td>
<td valign="top"> </td>
<td class="Center" valign="top"><img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/></td>
</tr>
<tr>
<td valign="top">X-ray barium enema single-contrast every 5 years after negative screen</td>
<td class="Center" valign="top">4</td>
<td valign="top">Use this procedure if CTC or DCBE cannot be performed.</td>
<td class="Center" valign="top"><img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/></td>
</tr>
<tr>
<td valign="top">MR colonography every 5 years after negative screen</td>
<td class="Center" valign="top">4</td>
<td valign="top"> </td>
<td class="Center" valign="top">O</td>
</tr>
</tbody>
<tfoot>
<tr>
<th valign="top" colspan="3"><span style="text-decoration: underline;">Rating Scale:</span> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate</th>
<th class="Center" valign="top">*Relative Radiation Level</th>
</tr>
</tfoot>
</table>
<p>Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.</p>
<p><strong><span style="text-decoration: underline;">Variant 2:</span> Average-risk individual after positive fecal occult blood test (FOBT), indicating a relative elevation in risk.</strong></p>
<table border="1" cellspacing="1" cellpadding="5" summary="Table: Variant 2: Average-risk individual after positive fecal occult blood test (FOBT), indicating a relative elevation in risk">
<thead>
<tr>
<th width="30%" class="Center" valign="bottom" scope="col">Radiologic Procedure</th>
<th width="20%" class="Center" valign="bottom" scope="col">Rating</th>
<th width="40%" class="Center" valign="bottom" scope="col">Comments</th>
<th width="25%" class="Center" valign="bottom" scope="col">RRL*</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top">CT colonography</td>
<td class="Center" valign="top">9</td>
<td valign="top"> </td>
<td class="Center" valign="top"><img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/></td>
</tr>
<tr>
<td valign="top">X-ray barium enema double-contrast</td>
<td class="Center" valign="top">6</td>
<td valign="top"> </td>
<td class="Center" valign="top"><img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/></td>
</tr>
<tr>
<td valign="top">X-ray barium enema single-contrast</td>
<td class="Center" valign="top">4</td>
<td valign="top">Use this procedure if CTC or DCBE cannot be performed.</td>
<td class="Center" valign="top"><img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/></td>
</tr>
<tr>
<td valign="top">MR colonography</td>
<td class="Center" valign="top">4</td>
<td valign="top"> </td>
<td class="Center" valign="top">O</td>
</tr>
</tbody>
<tfoot>
<tr>
<th valign="top" colspan="3"><span style="text-decoration: underline;">Rating Scale:</span> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate</th>
<th class="Center" valign="top">*Relative Radiation Level</th>
</tr>
</tfoot>
</table>
<p>Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.</p>
<p><strong><span style="text-decoration: underline;">Variant 3:</span> Average-, moderate-, or high-risk individual after incomplete colonoscopy.</strong></p>
<table border="1" cellspacing="1" cellpadding="5" summary="Table: Variant 3: Average-, moderate-, or high-risk individual after incomplete colonoscopy">
<thead>
<tr>
<th width="30%" class="Center" valign="bottom" scope="col">Radiologic Procedure</th>
<th width="20%" class="Center" valign="bottom" scope="col">Rating</th>
<th width="40%" class="Center" valign="bottom" scope="col">Comments</th>
<th width="25%" class="Center" valign="bottom" scope="col">RRL*</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top">CT colonography</td>
<td class="Center" valign="top">9</td>
<td valign="top"> </td>
<td class="Center" valign="top"><img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/></td>
</tr>
<tr>
<td valign="top">X-ray barium enema double-contrast</td>
<td class="Center" valign="top">6</td>
<td valign="top"> </td>
<td class="Center" valign="top"><img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/></td>
</tr>
<tr>
<td valign="top">X-ray barium enema single-contrast</td>
<td class="Center" valign="top">4</td>
<td valign="top">Use this procedure if CTC or DCBE cannot be performed.</td>
<td class="Center" valign="top"><img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/></td>
</tr>
<tr>
<td valign="top">MR colonography</td>
<td class="Center" valign="top">3</td>
<td valign="top"> </td>
<td class="Center" valign="top">O</td>
</tr>
</tbody>
<tfoot>
<tr>
<th valign="top" colspan="3"><span style="text-decoration: underline;">Rating Scale:</span> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate</th>
<th class="Center" valign="top">*Relative Radiation Level</th>
</tr>
</tfoot>
</table>
<p>Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.</p>
<p><strong><span style="text-decoration: underline;">Variant 4:</span> Moderate-risk individual: personal history of adenoma or carcinoma or first-degree family history of cancer or adenoma.</strong></p>
<table border="1" cellspacing="1" cellpadding="5" summary="Table: Variant 4: Moderate-risk individual: personal history of adenoma or carcinoma or first-degree family history of cancer or adenoma">
<thead>
<tr>
<th width="30%" class="Center" valign="bottom" scope="col">Radiologic Procedure</th>
<th width="20%" class="Center" valign="bottom" scope="col">Rating</th>
<th width="40%" class="Center" valign="bottom" scope="col">Comments</th>
<th width="25%" class="Center" valign="bottom" scope="col">RRL*</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top">CT colonography every 5 years after negative screen</td>
<td class="Center" valign="top">9</td>
<td valign="top"> </td>
<td class="Center" valign="top"><img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/></td>
</tr>
<tr>
<td valign="top">X-ray barium enema double-contrast every 5 years after negative screen</td>
<td class="Center" valign="top">6</td>
<td valign="top"> </td>
<td class="Center" valign="top"><img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/></td>
</tr>
<tr>
<td valign="top">X-ray barium enema single-contrast every 5 years after negative screen</td>
<td class="Center" valign="top">4</td>
<td valign="top">Use this procedure if CTC or DCBE cannot be performed.</td>
<td class="Center" valign="top"><img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/></td>
</tr>
<tr>
<td valign="top">MR colonography every 5 years after negative screen</td>
<td class="Center" valign="top">4</td>
<td valign="top"> </td>
<td class="Center" valign="top">O</td>
</tr>
</tbody>
<tfoot>
<tr>
<th valign="top" colspan="3"><span style="text-decoration: underline;">Rating Scale:</span> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate</th>
<th class="Center" valign="top">*Relative Radiation Level</th>
</tr>
</tfoot>
</table>
<p>Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.</p>
<p><strong><span style="text-decoration: underline;">Variant 5:</span> High-risk individual: hereditary nonpolyposis colorectal cancer.</strong></p>
<table border="1" cellspacing="1" cellpadding="5" summary="Table: Variant 5: High-risk individual: hereditary nonpolyposis colorectal cancer">
<thead>
<tr>
<th width="30%" class="Center" valign="bottom" scope="col">Radiologic Procedure</th>
<th width="20%" class="Center" valign="bottom" scope="col">Rating</th>
<th width="40%" class="Center" valign="bottom" scope="col">Comments</th>
<th width="25%" class="Center" valign="bottom" scope="col">RRL*</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top">CT colonography</td>
<td class="Center" valign="top">3</td>
<td valign="top">Colonoscopy is the preferred procedure.</td>
<td class="Center" valign="top"><img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/></td>
</tr>
<tr>
<td valign="top">X-ray barium enema double-contrast</td>
<td class="Center" valign="top">2</td>
<td valign="top">Colonoscopy is the preferred procedure.</td>
<td class="Center" valign="top"><img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/></td>
</tr>
<tr>
<td valign="top">MR colonography</td>
<td class="Center" valign="top">2</td>
<td valign="top"> </td>
<td class="Center" valign="top">O</td>
</tr>
<tr>
<td valign="top">X-ray barium enema single-contrast</td>
<td class="Center" valign="top">1</td>
<td valign="top">Use this procedure if CTC or DCBE cannot be performed.</td>
<td class="Center" valign="top"><img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif"/></td>
</tr>
</tbody>
<tfoot>
<tr>
<th valign="top" colspan="3"><span style="text-decoration: underline;">Rating Scale:</span> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate</th>
<th class="Center" valign="top">*Relative Radiation Level</th>
</tr>
</tfoot>
</table>
<p>Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.</p>
<p><strong><span style="text-decoration: underline;">Variant 6</span>: High-risk individual: ulcerative colitis or Crohn colitis.</strong></p>
<table border="1" cellspacing="1" cellpadding="5" summary="Table: Variant 6: High-risk individual: ulcerative colitis or Crohn colitis">
<thead>
<tr>
<th width="30%" class="Center" valign="bottom" scope="col">Radiologic Procedure</th>
<th width="20%" class="Center" valign="bottom" scope="col">Rating</th>
<th width="40%" class="Center" valign="bottom" scope="col">Comments</th>
<th width="25%" class="Center" valign="bottom" scope="col">RRL*</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top">CT colonography</td>
<td class="Center" valign="top">3</td>
<td valign="top">Colonoscopy is the preferred procedure for its ability to obtain biopsies to look for dysplasia.</td>
<td class="Center" valign="top"><img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/></td>
</tr>
<tr>
<td valign="top">X-ray barium enema double-contrast</td>
<td class="Center" valign="top">2</td>
<td valign="top">Colonoscopy is the preferred procedure for its ability to obtain biopsies to look for dysplasia.</td>
<td class="Center" valign="top"><img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/></td>
</tr>
<tr>
<td valign="top">MR colonography</td>
<td class="Center" valign="top">2</td>
<td valign="top">Colonoscopy is the preferred procedure for its ability to obtain biopsies to look for dysplasia.</td>
<td class="Center" valign="top">O</td>
</tr>
<tr>
<td valign="top">X-ray barium enema single-contrast</td>
<td class="Center" valign="top">1</td>
<td valign="top">Colonoscopy is the preferred procedure for its ability to obtain biopsies to look for dysplasia.</td>
<td class="Center" valign="top"><img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/></td>
</tr>
</tbody>
<tfoot>
<tr>
<th valign="top" colspan="3"><span style="text-decoration: underline;">Rating Scale:</span> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate</th>
<th class="Center" valign="top">*Relative Radiation Level</th>
</tr>
</tfoot>
</table>
<p>Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.</p>
<p><strong><span style="text-decoration: underline;">Summary of Literature Review</span></strong></p>
<p><strong>Introduction/Background</strong></p>
<p>Colorectal cancer is the third leading cause of cancer deaths in the United States. An average-risk individual has an approximately 5% lifetime risk of developing colorectal cancer. Detecting the disease when it is localized has long been associated with a 5-year survival rate of approximately 80%. Also, evidence has accumulated to support the concept that almost all colorectal cancers develop from benign adenomas and that, in most cases, this transformation process is slow, requiring an average of 10 years. More recently, a second pathway, mediated through benign hyperplastic or serrated polyps, has also been identified to have a long dwell time. However, such screening involves exposing healthy, asymptomatic individuals to tests that impose a financial burden on society and have the potential for physical and psychological injury to the patient. Thus, the decision to promote screening requires scientific evidence that it can be used to reduce mortality in a safe and cost-effective manner. Information extrapolated from symptomatic populations is not sufficient because of the possible influence of lead-time and length-time bias. In addition, determining whom to screen, how to screen, and how often to screen requires a complex integration of an individual's risk level, the test performance characteristics (sensitivity, specificity), the safety and cost of the screening options, and the natural history and prevalence of the target lesions.</p>
<p>Evidence from 3 randomized controlled trials using fecal occult blood testing (FOBT) in average-risk individuals (age ≥50 years) demonstrated a 15% to 33% mortality reduction. A nonrandomized trial with historical controls reported a reduction in the incidence of colon cancer by using colonoscopy to remove adenomas. Long-term follow-up after colonoscopic polypectomy has been found to result in a 53% reduction in mortality. A case-control study demonstrated that screening sigmoidoscopy decreased colorectal cancer mortality by two-thirds for cancers within reach of the sigmoidoscope, and another case-control study reported a reduction in the incidence of and mortality from colorectal cancer after removing adenomas in patients who had undergone colonic endoscopy because of symptoms. Results from these case-control studies have suggested a protective effect lasting 5 to 10 years after direct structural examination of the colon. The issue yet to be clarified is the potential benefit from the various screening options, the magnitude of which depends highly on test sensitivity, recommended test intervals, and the need to detect and remove all colonic polyps.</p>
<p>The prevalence of adenomas in the general population is 30% to 50% and increases with age. Most adenomas are diminutive (≤5 mm) or small (6–9 mm) in size. The rate of carcinoma is very low in subcentimeter adenomas, reported at 0.03% in diminutive polyps and 0.2% for 6- to 9-mm polyps. Even in larger adenomas measuring 10 to 20 mm in size, the rate remains relatively low—below 2%. Over time, only a tiny minority of all adenomas ultimately progress to cancer. The vast majority remain stable or regress over time. A longitudinal colonoscopic study reported a tendency for net regression in 6- to 9-mm adenomas over a 3-year period. On the other hand, adenomas >25 mm have a 10% chance of containing invasive cancer; polyps ≥10 mm have an 8% chance of progressing to invasive cancer at 10 years, which increases to 24% at 20 years. Individuals with a history of such neoplasms appear to have an increased probability of developing colorectal cancer in the future, whereas those who have had fewer than 3 small adenomas have a subsequent cancer risk similar to that of the general population.</p>
<p>A joint guideline from the American Cancer Society (ACS), the U.S. Multi-Society Task Force on Colorectal Cancer (USMSTF), and the American College of Radiology (ACR) has divided colorectal cancer risk levels into 3 categories: 1) average (individuals ≥50 years of age), 2) moderate (individuals with a personal history of a large adenoma or carcinoma or a first-degree relative with a history of adenoma or carcinoma), and 3) high (individuals with hereditary syndromes, such as hereditary nonpolyposis colorectal cancer and familial polyposis, or a personal history of ulcerative colitis or Crohn colitis).</p>
<p>The magnitude of risk for an individual who has a single, first-degree relative with colorectal cancer is approximately 2 to 3 times that of the general population. The risk increases as the number of first-degree relatives with the disease increases. In addition, the cancer tends to develop at a younger age, depending on the age at which the relative developed a neoplasm. The degree of risk for individuals with a personal history of neoplasm is unclear, because all the information on this subject was derived from the precolonoscopy era when complete colonic clearing was not performed; theoretically, then, residual synchronous lesions could have evolved. There is no evidence to indicate that the natural history of the disease in the 2 moderate-risk groups differs from that in the average-risk group. The probability of an individual with a hereditary nonpolyposis syndrome developing colorectal cancer may be as high as 50%.</p>
<p>The natural history of the disease in moderate risk individuals is uncertain. A nonrandomized controlled trial of such a population screened at 3-year intervals with a double-contrast barium enema (DCBE) and sigmoidoscopy or colonoscopy reported a significant reduction in cancer incidence.</p>
<p>The risk of cancer in individuals with ulcerative colitis increases after the disease has been present 8 to 10 years, and it correlates with the extent of the disease. The best estimates of risk are 5% after 10 to 20 years of disease and 9% per year thereafter. The risk for individuals with Crohn colitis may be comparable. Unlike the other forms of colorectal cancer screening, the screening of ulcerative colitis patients focuses on detecting dysplasia (which may be flat and identified only by random biopsies, or it may be macroscopically visible) and a subsequent prophylactic colectomy. There is no evidence of a reduction in mortality resulting from colorectal cancer screening in these patients, although annual colonoscopy screening has demonstrated a shift to early-stage detection. For patients at high risk due to known ulcerative colitis or Crohn colitis, a colonoscopy is preferred over computed tomography colonography (CTC), magnetic resonance imaging (MRI), or barium examinations due to its ability to obtain biopsies to look for dysplasia.</p>
<p><strong>Current Colorectal Cancer Screening Recommendations</strong></p>
<p>A discussion of the nonradiologic tests for colorectal cancer screening is beyond the scope of this document. However, of the structural tests available, colonoscopy is currently considered to be the most sensitive and specific for detecting colorectal polyps and cancers. A number of organizations—including the World Health Organization, the United States Agency for Health Care Policy and Research, and the United States Preventive Service Task Force—have issued or endorsed guidelines for colorectal cancer screening, which are presented as lists of options. For average-risk individuals, the options include annual or biennial FOBT, flexible sigmoidoscopy every 5 years, and colonoscopy every 10 years. The current joint ACS, USMSTF, and ACR guideline for colorectal cancer screening includes a DCBE or CTC every 5 years on the list of options for average-risk individuals. These guidelines also separate colorectal cancer screening tools into two categories: 1) those that can screen for both adenomatous polyps and cancer (flexible sigmoidoscopy, DCBE, CTC, and colonoscopy); and 2) those that are intended to screen for cancer only (FOBT, fecal immunochemical test, and stool DNA test). There are more specific recommendations for individuals who are at an increased risk for colorectal neoplasia.</p>
<p><strong>Double-contrast Barium Enema</strong></p>
<p>A retrospective study evaluated the diagnostic yield of DCBE examinations performed for colorectal cancer screening in average-risk individuals >50 years of age. The diagnostic yield was 5.1% for neoplastic lesions ≥10 mm and 6.2% for advanced neoplastic lesions, regardless of size. These diagnostic yields fall within the lower range of those reported for screening colonoscopy (5.0%–9.5% for colonic neoplasms ≥10 mm and 4.6%–11.7% for advanced colonic neoplasms, regardless of size).</p>
<p>The best data on the effectiveness of the DCBE for detecting colorectal cancer come from studies in which the imaging history of patients with colorectal cancer was reviewed. Based on this methodology, the sensitivity of DCBE ranges from 75 to 95%. When considering only localized cancer, the sensitivity varies from 58% to 94%. In studies comparing the DCBE to endoscopy, the sensitivity has been 80% to 100%, and when used to evaluate individuals with a positive FOBT, most reports indicate a sensitivity of 75% to 80%. This correlates with a large, population-based study that found the overall rate of new or missed cancers following a DCBE was 22%. The sensitivity of DCBE for detecting large adenomas has been best studied when all subjects underwent both radiologic and endoscopic procedures. With this study design, sensitivity has ranged from 48% to 81%.</p>
<p>It has been determined that the specificity of a DCBE for detecting large adenomas is 96%, and the negative predictive value is 98%. It has been frequently suggested that the DCBE is less effective at demonstrating polyps in the rectosigmoid colon. However, well-designed studies have shown that sensitivity figures for the DCBE in this anatomic region are comparable to those in other colonic sites. The diagnostic yield of the DCBE can be increased by supplementing it with a flexible sigmoidoscopy. In the workup of a positive FOBT, the combination of the two procedures detected 98% of large polyps and cancers. A cost-effectiveness analysis demonstrated that a DCBE performed every 5 to 10 years costs less than $22,000 per life-year saved for a possible range of natural history, which is far below the standard of $40,000. A DCBE is a safe procedure, with a perforation rate of approximately 1 in 25,000. The perforation rates associated with other colorectal examinations are 1 in 22,000 for CTC, 1 in 10,000 for a flexible sigmoidoscopy, and 1 in 1,000 for a diagnostic colonoscopy.</p>
<p><strong>Single-contrast Barium Enema</strong></p>
<p>A preponderance of the literature has demonstrated a markedly inferior performance profile for the single-contrast barium enema (SCBE). A minority of studies have suggested that a SCBE has the potential to be as sensitive as the DCBE for detecting cancer and large polyps. The reported sensitivity for cancer ranges from 82% to 95% and is approximately 95% for large polyps. However, because of the paucity of studies and limitations of the study designs, questions have been raised about the reproducibility of the results, particularly for large polyps. In an FOBT trial, SCBE was used as a diagnostic follow-up. The sensitivity for cancer was 80%.</p>
<p><strong>Computed Tomography Colonography</strong></p>
<p>CTC (also known as "virtual colonoscopy") was introduced in 1994 as a less invasive method of imaging the colon by using helical CT. Early CTC trials performed with single-detector CT scanners demonstrated sensitivities of 59% to 92% and specificities of 82% to 98% for polyps ≥10 mm. A meta-analysis of these early trials confirmed reasonably high, pooled sensitivities of 88% and 81% by patient and lesion, respectively, with a pooled specificity of 95% for polyps ≥10 mm [52]. Studies performed with 4-detector-row scanners have demonstrated sensitivities and specificities of 82% to 100% and 90% to 98%, respectively, for polyps ≥10 mm. However, most of these trials were not performed on screening populations but on individuals who were at an increased risk for colorectal neoplasia. A trial performed on 307 asymptomatic subjects using a 64 multidetector-row CT demonstrated a CTC sensitivity and specificity of 91% and 93%, respectively, for polyps >6 mm and 92% and 98%, respectively, for polyps ≥10 mm.</p>
<p>Two other meta-analyses of CTC performance in detecting ≥10 mm polyps showed pooled sensitivities by patient of 85% and 93%, with pooled specificities of 97%. One meta-analysis compared 7 studies that used multidetector CT with 9 studies that used single-detector CT and found that multidetector CT had a high overall sensitivity of 95% for polyp detection, whereas single-detector CT had an overall sensitivity of 82%.</p>
<p>Multiple large, multicenter trials comparing multidetector-row CTC and optical colonoscopy for detecting colorectal polyps and cancers have been published. Earlier multicenter trials had conflicting results. In a study of 1,233 asymptomatic average-risk individuals undergoing colorectal cancer screening, the sensitivities of CTC and colonoscopy for detecting adenomatous polyps ≥10 mm were 94% and 88%, respectively. However, in a smaller second study, which included 600 patients referred for clinically indicated colonoscopy, the sensitivities of CTC and colonoscopy for detecting patients with polyps ≥10 mm were 55% and 100%, respectively. In a third study, which included 614 individuals at increased risk for colorectal neoplasia, the sensitivities of CTC and colonoscopy were 59% and 98%, respectively. These discrepant results were likely related to differences in study design and reader experience. Older CTC techniques were used in the studies with poor CTC results, and the lack of reader training was likely a major contributing factor. For example, in the third study only 1 of 9 centers involved in that trial had substantial prior experience with CTC, and the only requirement to be a reader was performance of at least 10 CTC procedures (without any test of accuracy). For the institution with prior CTC experience, the sensitivity for polyps ≥10 mm was 82%, compared with 24% for the other 8 institutions.</p>
<p>Many of the issues regarding colonic preparation and reader training were addressed in the largest U.S. multicenter trial to date. In the American College of Radiology Imaging Network (ACRIN) National CTC Trial, 15 sites recruited a total of 2,531 asymptomatic patients, who underwent multidetector-row CTC (16 rows or more) with stool and fluid tagging and mechanical carbon dioxide insufflation of the colon. All participating radiologists had to complete a qualifying examination, with a minimum accuracy of 90% for large polyps. Per-patient sensitivity, specificity, and positive and negative predictive values were 90%, 86%, 23%, and 99%, respectively, for detecting ≥10 mm adenomas or cancers. The per-patient sensitivity for detecting adenomas ≥6 mm was 78%. The per-polyp sensitivity for ≥10 mm adenomas or cancers was 84%. When comparing primary 2-dimensional (2-D) and primary 3-dimensional (3-D) interpretation methods, no difference in sensitivity was identified for the detection of large polyps. A multicenter trial performed in 937 individuals at increased risk for colorectal cancer reported similar per-patient sensitivity, specificity, and negative predictive values of 85%, 88%, and 96%, respectively, for advanced neoplasia ≥6 mm, but there was a higher positive predictive value of 62%.</p>
<p>The diagnostic yields of CTC and colonoscopy for advanced neoplasia were compared in parallel screening programs. Primary CTC screening in 3,120 patients was compared with primary colonoscopy screening in 3,163 subjects. Similar detection rates were found for CTC and colonoscopy screening, which identified 123 and 121 advanced neoplasms, respectively. The referral rate for colonoscopy in the CTC group was 8%. The total numbers of polyps removed in the CTC and colonoscopy groups were 561 and 2,434, respectively. Seven perforations occurred in the colonoscopy group, but there were none in the CTC group. A review of a 1-year CTC screening experience for colorectal neoplasia showed that 3.9% of individuals had 1 polyp ≥1 cm, and 6.9% had ≥1 polyps 6 to 9 mm. Of the 71 patients who chose colonoscopy for further evaluation of these polyps, concordant lesions were found with colonoscopy in 65 (91.5% positive predictive value). In addition, the outcomes of patients with negative CTC screens have also been reported. A longitudinal follow-up of 1,011 patients over nearly 5 years demonstrated a single-interval cancer (crude cancer incidence of 0.2 cancers per 1,000 patient years), leading to the conclusion that a 5-year routine screen interval and nonreporting of diminutive lesions (≤5 mm) were appropriate strategies.</p>
<p>CTC performance has been evaluated in senior patient cohorts (age ≥65 years). A retrospective analysis of 577 subjects found an excellent CTC-colonoscopy concordance rate of 91%. Based on a 6-mm threshold, there was an overall patient referral rate of 15% for colonoscopy. Considering only adenomas, the per-patient positivity rates for 6- and 10-mm thresholds were 11% and 7%, respectively. When comparing 204 nonsenior (14%) and 250 senior patients (13%) undergoing CTC, another study found no statistically significant difference in the percentage of individuals with at least 1 polyp ≥6 mm. A post hoc analysis of 477 senior patients from the ACRIN National CTC Trial demonstrated that for large neoplasms, sensitivity and specificity among the older cohort were 82% and 83%, respectively. There was no statistically significant difference when compared with the sensitivity and specificity of 92% and 86%, respectively, for lesions ≥10 mm in the younger patient cohort. For lesions >6 mm, the sensitivity and specificity were 72% and 86%, respectively, for older patients and 81% and 89%, respectively, for younger patients, with no statistically significant difference. Another study reporting outcomes of 1,400 senior patients who underwent CTC found a 15% frequency for referral to colonoscopy at a polyp threshold of 6 mm. Colorectal neoplasia was identified in 9% of patients, and advanced neoplasia was found in 3%.</p>
<p>Adherence to the ACR practice guideline for performing CTC in adults should help eliminate some of the variability reported in earlier published studies. This guideline also includes suggestions regarding the interpretation and reporting of extracolonic findings. To avoid unnecessary further workup and patient anxiety, caution is emphasized when reporting findings that are likely to be of low clinical significance. There is evidence that using structured reporting constructs, such as CT Colonography Reporting and Data System, can decrease workups to <10%. Unsuspected extracolonic malignancies and previously unknown aortic aneurysms are detected with CTC examinations in approximately 2% to 3% of patients.</p>
<p>Currently, most third-party payers provide reimbursement for screening CTC only after a failed colonoscopy or, in some cases, for individuals who have a contraindication to colonoscopy (e.g., those on chronic anticoagulation or with severe chronic lung disease who are at risk for undergoing sedation). Several studies have demonstrated the usefulness of CTC in individuals who have undergone an incomplete colonoscopy. In a study of 546 patients who underwent CTC after an incomplete colonoscopy, 13% were found to have lesions ≥6 mm. Per-patient and per-lesion positive predictive values of CTC for masses and large polyps were 91% and 92%, respectively.</p>
<p>A meta-analysis comparing the performance of the DCBE with CTC for detecting polyps ≥6 mm included 11 studies of DCBE (5,995 patients, 1,548 polyps) and 30 studies of CTC (6,573 patients, 2,348 polyps). Despite the inclusion of CTC studies with older techniques, statistically lower sensitivity and specificity were still seen for the DCBE compared with CTC.</p>
<p><strong>Magnetic Resonance Colonography</strong></p>
<p>MR colonography (MRC), which was introduced approximately 3 years after CTC, has the advantage that it does not use ionizing radiation. However, the spatial resolution of MRC is less than that of CTC, and MRC requires colonic distension with a liquid (a diluted gadolinium solution for "bright lumen" [T1-weighted]) imaging or tap water for "dark lumen" (T1-weighted) imaging. Clinical studies comparing MRC with optical colonoscopy have reported sensitivities of 93% to 100% for polyps ≥10 mm. One study compared polyp detection rates between dark and bright lumen MRC in 37 patients. Dark lumen MRC was better, with respective sensitivities of 79% and 68%, respectively, for detecting polyps >5 mm. Nevertheless, experience with MRC is extremely limited, especially outside of Europe. In a systematic review of 13 prospective studies evaluating MRC performance in 1,285 patients, the per-patient sensitivity and specificity for polyps ≥10 mm were 88% and 99%, respectively. On a per-polyp basis, polyps of ≥10 mm were detected with a sensitivity of 84%. The data were found to be too heterogeneous for diminutive polyps <6 mm and for small polyps measuring 6–9 mm.</p>
<p><strong>Role of Local Expertise</strong></p>
<p>Overall, the most appropriate imaging test for colorectal cancer screening is CTC. However, CTC expertise may not be available in all geographic areas. Thus, a DCBE may be the only imaging option in a particular area, despite its lower performance profile. The choice between these 2 tests may ultimately depend on local imaging expertise and on physician and patient preference.</p>
<p><strong>Summary</strong></p>
<ul style="list-style-type: disc;">
<li>CTC has emerged as the leading imaging technique for colorectal cancer screening. </li>
<li>DCBE remains an imaging test that may be appropriate for colorectal cancer screening, particularly when CTC is not available. </li>
<li>CTC is the preferred test following an incomplete optical colonoscopy. </li>
<li>Imaging tests including CTC and barium enema are usually not appropriate for colorectal cancer screening in high-risk patients with hereditary nonpolyposis colorectal cancer and inflammatory bowel disease. </li>
</ul>
<p><strong>Abbreviations</strong></p>
<ul style="list-style-type: disc;">
<li>CT, computed tomography </li>
<li>CTC, computed tomography colonography </li>
<li>DCBE, double-contrast barium enema </li>
<li>MR, magnetic resonance </li>
</ul>
<p><strong>Relative Radiation Level Designations</strong></p>
<table width="50%" border="1" cellspacing="1" cellpadding="5" summary="Table: Relative Radiation Level Definitions">
<thead>
<tr>
<th class="Center" valign="top">Relative Radiation Level*</th>
<th class="Center" valign="top">Adult Effective Dose Estimate Range</th>
<th class="Center" valign="top">Pediatric Effective Dose Estimate Range</th>
</tr>
</thead>
<tbody>
<tr>
<td class="Center" valign="top">O</td>
<td class="Center" valign="top">0 mSv</td>
<td class="Center" valign="top">0 mSv</td>
</tr>
<tr>
<td class="Center" valign="top"><img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/></td>
<td class="Center" valign="top"><0.1 mSv</td>
<td class="Center" valign="top"><0.03 mSv</td>
</tr>
<tr>
<td class="Center" valign="top"><img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/></td>
<td class="Center" valign="top">0.1-1 mSv</td>
<td class="Center" valign="top">0.03-0.3 mSv</td>
</tr>
<tr>
<td class="Center" valign="top"><img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/></td>
<td class="Center" valign="top">1-10 mSv</td>
<td class="Center" valign="top">0.3-3 mSv</td>
</tr>
<tr>
<td class="Center" valign="top"><img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/></td>
<td class="Center" valign="top">10-30 mSv</td>
<td class="Center" valign="top">3-10 mSv</td>
</tr>
<tr>
<td class="Center" valign="top"><img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive" src="https://web.archive.org/web/20180713052618im_/http://guideline.gov/images/image_radioactive.gif "/></td>
<td class="Center" valign="top">30-100 mSv</td>
<td class="Center" valign="top">10-30 mSv</td>
</tr>
<tr>
<td valign="top" colspan="3">*RRL assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (e.g., region of the body exposed to ionizing radiation, the imaging guidance that is used). The RRLs for these examinations are designated as "Varies".</td>
</tr>
</tbody>
</table></div></p>
<h3><a href="#">Clinical Algorithm(s)</a></h3>
<p><div class="content_para"><p>Algorithms were not developed from criteria guidelines.</p></div></p>
</div>
<h2 id="396" class="accordion-title section-396 is-active" role="tab" aria-expanded="true"><a href="#">Scope</a></h2>
<div class="accordion-panel is-active" role="tabpanel">
<h3><a href="#">Disease/Condition(s)</a></h3>
<p><div class="content_para"><p>Colorectal cancer</p></div></p>
<h3><a href="#">Guideline Category</a></h3>
<p>Diagnosis</p>
<p>Screening</p>
<h3><a href="#">Clinical Specialty</a></h3>
<p>Family Practice</p>
<p>Gastroenterology</p>
<p>Internal Medicine</p>
<p>Oncology</p>
<p>Preventive Medicine</p>
<p>Radiology</p>
<h3><a href="#">Intended Users</a></h3>
<p>Health Plans</p>
<p>Hospitals</p>
<p>Managed Care Organizations</p>
<p>Physicians</p>
<p>Utilization Management</p>
<h3><a href="#">Guideline Objective(s)</a></h3>
<p><div class="content_para"><p>To evaluate the appropriateness of initial radiologic examinations for colorectal cancer screening</p></div></p>
<h3><a href="#">Target Population</a></h3>
<p><div class="content_para"><p>Adult population at average, moderate, and high colorectal cancer risk levels</p></div></p>
<h3><a href="#">Interventions and Practices Considered</a></h3>
<p><ol style="list-style-type: decimal;">
<li>Computed tomography colonography (CTC)</li>
<li>X-ray, barium enema
<ul style="list-style-type: disc;">
<li>Double-contrast </li>
<li>Single-contrast </li>
</ul>
</li>
<li>Magnetic resonance colonography (MRC)</li>
</ol></p>
<h3><a href="#">Major Outcomes Considered</a></h3>
<p><ul style="list-style-type: disc;">
<li>Mortality </li>
<li>Utility of radiologic examinations in differential diagnosis and screening </li>
</ul></p>
</div>
<h2 id="405" class="accordion-title section-405 is-active" role="tab" aria-expanded="true"><a href="#">Methodology</a></h2>
<div class="accordion-panel is-active" role="tabpanel">
<h3><a href="#">Methods Used to Collect/Select the Evidence</a></h3>
<p>Searches of Electronic Databases</p>
<h3><a href="#">Description of Methods Used to Collect/Select the Evidence</a></h3>
<p><div class="content_para"><p><strong>Literature Search Procedure</strong></p>
<p>Staff will search in PubMed only for peer reviewed medical literature for routine searches. Any article or guideline may be used by the author in the narrative but those materials may have been identified outside of the routine literature search process.</p>
<p>The Medline literature search is based on keywords provided by the topic author. The two general classes of keywords are those related to the condition (e.g., ankle pain, fever) and those that describe the diagnostic or therapeutic intervention of interest (e.g., mammography, MRI).</p>
<p>The search terms and parameters are manipulated to produce the most relevant, current evidence to address the American College of Radiology Appropriateness Criteria (ACR AC) topic being reviewed or developed. Combining the clinical conditions and diagnostic modalities or therapeutic procedures narrows the search to be relevant to the topic. Exploding the term "diagnostic imaging" captures relevant results for diagnostic topics.</p>
<p>The following criteria/limits are used in the searches.</p>
<ol style="list-style-type: decimal;" start="1">
<li>Articles that have abstracts available and are concerned with humans. </li>
<li>Restrict the search to the year prior to the last topic update or in some cases the author of the topic may specify which year range to use in the search. For new topics, the year range is restricted to the last 10 years unless the topic author provides other instructions. </li>
<li>May restrict the search to Adults only or Pediatrics only. </li>
<li>Articles consisting of only summaries or case reports are often excluded from final results. </li>
</ol>
<p>The search strategy may be revised to improve the output as needed.</p></div></p>
<h3><a href="#">Number of Source Documents</a></h3>
<p><div class="content_para"><p>The total number of source documents identified as the result of the literature search is not known.</p></div></p>
<h3><a href="#">Methods Used to Assess the Quality and Strength of the Evidence</a></h3>
<p>Weighting According to a Rating Scheme (Scheme Given)</p>
<h3><a href="#">Rating Scheme for the Strength of the Evidence</a></h3>
<p><div class="content_para"><p><strong>Strength of Evidence Key</strong></p>
<p>Category 1 - The conclusions of the study are valid and strongly supported by study design, analysis and results.</p>
<p>Category 2 - The conclusions of the study are likely valid, but study design does not permit certainty.</p>
<p>Category 3 - The conclusions of the study may be valid but the evidence supporting the conclusions is inconclusive or equivocal.</p>
<p>Category 4 - The conclusions of the study may not be valid because the evidence may not be reliable given the study design or analysis.</p></div></p>
<h3><a href="#">Methods Used to Analyze the Evidence</a></h3>
<p>Review of Published Meta-Analyses</p>
<p>Systematic Review with Evidence Tables</p>
<h3><a href="#">Description of the Methods Used to Analyze the Evidence</a></h3>
<p><div class="content_para"><p>The topic author drafts or revises the narrative text summarizing the evidence found in the literature. American College of Radiology (ACR) staff draft an evidence table based on the analysis of the selected literature. These tables rate the strength of the evidence (study quality) for each article included in the narrative text.</p>
<p>The expert panel reviews the narrative text, evidence table, and the supporting literature for each of the topic-variant combinations and assigns an appropriateness rating for each procedure listed in the table. Each individual panel member assigns a rating based on his/her interpretation of the available evidence.</p>
<p>More information about the evidence table development process can be found in the ACR Appropriateness Criteria® Evidence Table Development document (see the "Availability of Companion Documents" field).</p></div></p>
<h3><a href="#">Methods Used to Formulate the Recommendations</a></h3>
<p>Expert Consensus (Delphi)</p>
<h3><a href="#">Description of Methods Used to Formulate the Recommendations</a></h3>
<p><div class="content_para"><p><strong>Rating Appropriateness</strong></p>
<p>The appropriateness ratings for each of the procedures included in the Appropriateness Criteria topics are determined using a modified Delphi methodology. A series of surveys are conducted to elicit each panelist's expert interpretation of the evidence, based on the available data, regarding the appropriateness of an imaging or therapeutic procedure for a specific clinical scenario. American College of Radiology (ACR) staff distribute surveys to the panelists along with the evidence table and narrative. Each panelist interprets the available evidence and rates each procedure. The surveys are completed by panelists without consulting other panelists. The appropriateness rating scale is an ordinal scale that uses integers from 1 to 9 grouped into three categories: 1, 2, or 3 are in the category "usually not appropriate"; 4, 5, or 6 are in the category "may be appropriate"; and 7, 8, or 9 are in the category "usually appropriate." Each panel member assigns one rating for each procedure for a clinical scenario. The ratings assigned by each panel member are presented in a table displaying the frequency distribution of the ratings without identifying which members provided any particular rating.</p>
<p>If consensus is reached, the median rating is assigned as the panel's final recommendation/rating. Consensus is defined as eighty percent (80%) agreement within a rating category. A maximum of three rounds may be conducted to reach consensus. Consensus among the panel members must be achieved to determine the final rating for each procedure.</p>
<p>If consensus is not reached, the panel is convened by conference call. The strengths and weaknesses of each imaging procedure that has not reached consensus are discussed and a final rating is proposed. If the panelists on the call agree, the rating is proposed as the panel's consensus. The document is circulated to all the panelists to make the final determination. If consensus cannot be reached on the call or when the document is circulated, "No consensus" appears in the rating column and the reasons for this decision are added to the comment sections.</p>
<p>This modified Delphi method enables each panelist to express individual interpretations of the evidence and his or her expert opinion without excessive influence from fellow panelists in a simple, standardized and economical process. A more detailed explanation of the complete process can be found in additional methodology documents found on the <a href="/web/20180713052618/https://www.guideline.gov/Home/Disclaimer?id=47650&contentType=summary&redirect=http%3a%2f%2fwww.acr.org%2fac" title="ACR Web site">ACR Web site</a> <img alt="External Web Site Policy" src="/web/20180713052618im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/> (see also the "Availability of Companion Documents" field).</p></div></p>
<h3><a href="#">Rating Scheme for the Strength of the Recommendations</a></h3>
<p><div class="content_para"><p>Not applicable</p></div></p>
<h3><a href="#">Cost Analysis</a></h3>
<p><div class="content_para"><p>A cost-effectiveness analysis demonstrated that a double-contrast barium enema (DCBE) performed every 5 to 10 years costs less than $22,000 per life-year saved for a possible range of natural history, which is far below the standard of $40,000.</p></div></p>
<h3><a href="#">Method of Guideline Validation</a></h3>
<p>Internal Peer Review</p>
<h3><a href="#">Description of Method of Guideline Validation</a></h3>
<p><div class="content_para"><p>Criteria developed by the Expert Panels are reviewed by the American College of Radiology (ACR) Committee on Appropriateness Criteria.</p></div></p>
</div>
<h2 id="424" class="accordion-title section-424 is-active" role="tab" aria-expanded="true"><a href="#">Evidence Supporting the Recommendations</a></h2>
<div class="accordion-panel is-active" role="tabpanel">
<h3><a href="#">Type of Evidence Supporting the Recommendations</a></h3>
<p><div class="content_para"><p>The recommendations are based on analysis of the current literature and expert panel consensus.</p></div></p>
</div>
<h2 id="427" class="accordion-title section-427 is-active" role="tab" aria-expanded="true"><a href="#">Benefits/Harms of Implementing the Guideline Recommendations</a></h2>
<div class="accordion-panel is-active" role="tabpanel">
<h3><a href="#">Potential Benefits</a></h3>
<p><div class="content_para"><p>Selection of appropriate radiologic imaging procedures for colorectal cancer screening</p></div></p>
<h3><a href="#">Potential Harms</a></h3>
<p><div class="content_para"><p>A double-contrast barium enema (DCBE) is a safe procedure, with a perforation rate of approximately 1 in 25,000. The perforation rates associated with other colorectal examinations are 1 in 22,000 for computed tomography colonography (CTC), 1 in 10,000 for a flexible sigmoidoscopy, and 1 in 1,000 for a diagnostic colonoscopy.</p>
<p><strong>Relative Radiation Level (RRL)</strong></p>
<p>Potential adverse health effects associated with radiation exposure are an important factor to consider when selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, a relative radiation level indication has been included for each imaging examination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure. Patients in the pediatric age group are at inherently higher risk from exposure, both because of organ sensitivity and longer life expectancy (relevant to the long latency that appears to accompany radiation exposure). For these reasons, the RRL dose estimate ranges for pediatric examinations are lower as compared to those specified for adults. Additional information regarding radiation dose assessment for imaging examinations can be found in the American College of Radiology (ACR) Appropriateness Criteria® Radiation Dose Assessment Introduction document (see the "Availability of Companion Documents" field).</p></div></p>
</div>
<h2 id="430" class="accordion-title section-430 is-active" role="tab" aria-expanded="true"><a href="#">Contraindications</a></h2>
<div class="accordion-panel is-active" role="tabpanel">
<h3><a href="#">Contraindications</a></h3>
<p><div class="content_para"><p>Colonoscopy is contraindicated in patients on chronic anticoagulation or those with severe chronic lung disease who are at risk for undergoing sedation.</p></div></p>
</div>
<h2 id="432" class="accordion-title section-432 is-active" role="tab" aria-expanded="true"><a href="#">Qualifying Statements</a></h2>
<div class="accordion-panel is-active" role="tabpanel">
<h3><a href="#">Qualifying Statements</a></h3>
<p><div class="content_para"><p>The American College of Radiology (ACR) Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists, and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those exams generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the U.S. Food and Drug Administration (FDA) have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.</p></div></p>
</div>
<h2 id="434" class="accordion-title section-434 is-active" role="tab" aria-expanded="true"><a href="#">Implementation of the Guideline</a></h2>
<div class="accordion-panel is-active" role="tabpanel">
<h3><a href="#">Description of Implementation Strategy</a></h3>
<p><div class="content_para"><p>An implementation strategy was not provided.</p></div></p>
</div>
<h2 id="439" class="accordion-title section-439 is-active" role="tab" aria-expanded="true"><a href="#">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></h2>
<div class="accordion-panel is-active" role="tabpanel">
<h3><a href="#">IOM Care Need</a></h3>
<p>Staying Healthy</p>
<h3><a href="#">IOM Domain</a></h3>
<p>Effectiveness</p>
<p>Patient-centeredness</p>
</div>
<h2 id="442" class="accordion-title section-442 is-active" role="tab" aria-expanded="true"><a href="#">Identifying Information and Availability</a></h2>
<div class="accordion-panel is-active" role="tabpanel">
<h3><a href="#">Bibliographic Source(s)</a></h3>
<p><table><tr><td>Yee J, Kim DH, Rosen MP, Lalani T, Carucci LR, Cash BD, Feig BW, Fowler KJ, Katz DS, Smith MP, Yaghmai V, Expert Panel on Gastrointestinal Imaging. ACR Appropriateness Criteria® colorectal cancer screening. [online publication]. Reston (VA): American College of Radiology (ACR); 2013. 12 p. [90 references]</td></tr></table></p>
<h3><a href="#">Adaptation</a></h3>
<p><div class="content_para"><p>Not applicable: The guideline was not adapted from another source.</p></div></p>
<h3><a href="#">Date Released</a></h3>
<p>1998 (revised 2013)</p>
<h3><a href="#">Guideline Developer(s)</a></h3>
<p>American College of Radiology - Medical Specialty Society</p>
<h3><a href="#">Source(s) of Funding</a></h3>
<p><div class="content_para"><p>The American College of Radiology (ACR) provided the funding and the resources for these ACR Appropriateness Criteria®.</p></div></p>
<h3><a href="#">Guideline Committee</a></h3>
<p><div class="content_para"><p>Committee on Appropriateness Criteria, Expert Panel on Gastrointestinal Imaging</p></div></p>
<h3><a href="#">Composition of Group That Authored the Guideline</a></h3>
<p><div class="content_para"><p><em>Panel Members</em>: Judy Yee, MD (<em>Principal Author</em>); David H. Kim, MD (<em>Co-Author</em>); Max P. Rosen, MD, MPH (<em>Panel Chair</em>); Tasneem Lalani, MD (<em>Panel Vice-chair</em>); Laura R. Carucci, MD; Brooks D. Cash, MD; Barry W. Feig, MD; Kathryn J. Fowler, MD; Douglas S. Katz, MD; Martin P. Smith, MD; Vahid Yaghmai, MD, MS</p></div></p>
<h3><a href="#">Financial Disclosures/Conflicts of Interest</a></h3>
<p><div class="content_para"><p>Not stated</p></div></p>
<h3><a href="#">Guideline Status</a></h3>
<p><div class="content_para"><p>This is the current release of the guideline.</p>
<p>This guideline updates a previous version: Yee J, Rosen MP, Blake MA, Baker ME, Cash BD, Fidler JL, Grant TH, Greene FL, Jones B, Katz DS, Lalani T, Miller FH, Small WC, Sudakoff GS, Warshauer DM, Expert Panel on Gastrointestinal Imaging. ACR Appropriateness Criteria® colorectal cancer screening. [online publication]. Reston (VA): American College of Radiology (ACR); 2010. 9 p.</p></div></p>
<h3><a href="#">Guideline Availability</a></h3>
<p><div class="content_para"><p>Available from the <a href="/web/20180713052618/https://www.guideline.gov/Home/Disclaimer?id=47650&contentType=summary&redirect=https%3a%2f%2facsearch.acr.org%2fdocs%2f69469%2fNarrative" title="ACR Web site">American College of Radiology (ACR) Web site</a> <img alt="External Web Site Policy" src="/web/20180713052618im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>.</p>
<p>Print copies: Available from the American College of Radiology, 1891 Preston White Drive, Reston, VA 20191. Telephone: (703) 648-8900.</p></div></p>
<h3><a href="#">Availability of Companion Documents</a></h3>
<p><div class="content_para"><p>The following are available:</p>
<ul style="list-style-type: disc;">
<li>ACR Appropriateness Criteria®. Overview. Reston (VA): American College of Radiology; 2013 Nov. 3 p. Available from the <a href="/web/20180713052618/https://www.guideline.gov/Home/Disclaimer?id=47650&contentType=summary&redirect=http%3a%2f%2fwww.acr.org%2f%7e%2fmedia%2fACR%2fDocuments%2fAppCriteria%2fOverview.pdf" title="ACR Web site">American College of Radiology (ACR) Web site</a> <img alt="External Web Site Policy" src="/web/20180713052618im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
<li>ACR Appropriateness Criteria®. Literature search process. Reston (VA): American College of Radiology; 2013 Apr. 1 p. Available from the <a href="/web/20180713052618/https://www.guideline.gov/Home/Disclaimer?id=47650&contentType=summary&redirect=http%3a%2f%2fwww.acr.org%2f%7e%2fmedia%2fACR%2fDocuments%2fAppCriteria%2fLiteratureSearchProcess.pdf" title="ACR Web site">ACR Web site</a> <img alt="External Web Site Policy" src="/web/20180713052618im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
<li>ACR Appropriateness Criteria®. Evidence table development. Reston (VA): American College of Radiology; 2015 Nov. 5 p. Available from the <a href="/web/20180713052618/https://www.guideline.gov/Home/Disclaimer?id=47650&contentType=summary&redirect=https%3a%2f%2fwww.acr.org%2f%7e%2fmedia%2fACR%2fDocuments%2fAppCriteria%2fEvidenceTableDevelopment.pdf%3fdb%3dweb" title="ACR Web site">ACR Web site</a> <img alt="External Web Site Policy" src="/web/20180713052618im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
<li>ACR Appropriateness Criteria®. Radiation dose assessment introduction. Reston (VA): American College of Radiology; 2 p. Available from the <a href="/web/20180713052618/https://www.guideline.gov/Home/Disclaimer?id=47650&contentType=summary&redirect=http%3a%2f%2fwww.acr.org%2f%7e%2fmedia%2fACR%2fDocuments%2fAppCriteria%2fRadiationDoseAssessmentIntro.pdf" title="ACR Web site">ACR Web site</a> <img alt="External Web Site Policy" src="/web/20180713052618im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
<li>ACR Appropriateness Criteria®. Procedure information. Reston (VA): American College of Radiology; 1 p. Available from the <a href="/web/20180713052618/https://www.guideline.gov/Home/Disclaimer?id=47650&contentType=summary&redirect=http%3a%2f%2fwww.acr.org%2f%257E%2fmedia%2fE77E9964C8224151BE6D21A7CE68FEE4.pdf" title="ACR Web site">ACR Web site</a> <img alt="External Web Site Policy" src="/web/20180713052618im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
<li>ACR Appropriateness Criteria® colorectal cancer screening. Evidence table. Reston (VA): American College of Radiology; 2013. 24 p. Available from the <a href="/web/20180713052618/https://www.guideline.gov/Home/Disclaimer?id=47650&contentType=summary&redirect=https%3a%2f%2facsearch.acr.org%2fdocs%2f69469%2fET" title="ACR Web site">ACR Web site</a> <img alt="External Web Site Policy" src="/web/20180713052618im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
</ul></div></p>
<h3><a href="#">Patient Resources</a></h3>
<p><div class="content_para"><p>None available</p></div></p>
<h3><a href="#">NGC Status</a></h3>
<p><div class="content_para"><p>This summary was completed by ECRI on March 19, 2001. The information was verified by the guideline developer on March 29, 2001. This NGC summary was updated by ECRI Institute on April 26, 2007. This NGC summary was updated by ECRI Institute on November 30, 2010. This NGC summary was updated by ECRI Institute on February 27, 2014.</p></div></p>
<h3><a href="#">Copyright Statement</a></h3>
<p><div class="content_para"><p>Instructions for downloading, use, and reproduction of the American College of Radiology (ACR) Appropriateness Criteria® may be found on the <a href="/web/20180713052618/https://www.guideline.gov/Home/Disclaimer?id=47650&contentType=summary&redirect=http%3a%2f%2fwww.acr.org%2fQuality-Safety%2fAppropriateness-Criteria%2fTermsConditions" title="ACR Web site">ACR Web site</a> <img alt="External Web Site Policy" src="/web/20180713052618im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>.</p></div></p>
</div>
<h2 id="99999" class="accordion-title section-99999 is-active" role="tab" aria-expanded="true"><a href="#">Disclaimer</a></h2>
<div class="accordion-panel is-active" role="tabpanel">
<h3><a href="#">NGC Disclaimer</a></h3>
<p><p>The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p>
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p>
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href="/web/20180713052618/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria">NGC Inclusion Criteria</a>.</p>
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p>
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p></p>
</div>
</div>
<!-- /.accordion-container -->
<!-- ASIDE -->
<!-- FOOTER -->
</div><!-- /.article -->
</div><!-- /.content -->
<div class="aside">
<!-- About NGC -->
<div class="info-block">
<h3 class="info prefix-icon large-icon">About NGC Guideline Summaries</h3>
<p>NGC provides structured summaries containing information from clinical practice guidelines.</p>
<ul>
<li><a href="/web/20180713052618/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria" class="internal-link">Inclusion Criteria</a></li>
<li><a href="/web/20180713052618/https://www.guideline.gov/help-and-about/summaries/template-of-guideline-attributes" class="internal-link">Template of Guideline Attributes</a></li>
<li><a href="/web/20180713052618/https://www.guideline.gov/help-and-about/summaries/classification-scheme" class="internal-link">Classification Scheme</a></li>
</ul>
<p><a href="/web/20180713052618/https://www.guideline.gov/help-and-about/summaries/faqs" class="help-button">Guideline Summary FAQs</a></p>